Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07469488) titled 'A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens' on March 3.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Condition:
NSCLC (Advanced Non-small Cell Lung Cancer)
VTE (Venous Thromboembolism)
Rash Due to Epidermal Growth Factor Receptor Inhibitors
Infusion Reaction
Intervention:
Combination Product: Enha...